Table 4.
Univariate and multivariate Cox regression model for RFS and OS by individual cytogenetic lesion
| RFS | OS | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Unadjusted HR | Unadjusted 95% CI | Unadjusted P | Adjusted HR | Adjusted 95% CI | Adjusted P | Unadjusted HR | Unadjusted 95% CI | Unadjusted P | Adjusted HR | Adjusted 95% CI | Adjusted P | |
| KMT2A rearrangement, all | ||||||||||||
| All others KMT2Ar, all |
REF 1.597 |
REF 0.862-2.958 |
REF .1365 |
REF 1.943 |
REF 0.903-4.179 |
REF .0892 |
REF 1.899 |
REF 0.996-3.619 |
REF .0514 |
REF 2.589 |
REF 1.153-5.811 |
REF .0212 |
| KMT2A rearrangement, infant | ||||||||||||
| All others KMT2Ar, infant leukemia* |
REF 0.966 |
REF 0.353-2.649 |
REF .9471 |
REF 0.774 |
REF 0.207-2.897 |
REF .7040 |
REF 1.804 |
REF 0.724-4.498 |
REF .2052 |
REF 3.639 |
REF 1.039-12.746 |
REF .0434 |
| Ph+ | ||||||||||||
| All others Ph+ |
REF 0.222 |
REF 0.054-0.904 |
REF .0356 |
REF 0.304 |
REF 0.073-1.267 |
REF .1021 |
REF 0.305 |
REF 0.075-1.245 |
REF .0981 |
REF 0.409 |
REF 0.098-1.713 |
REF .2211 |
| Ph-like | ||||||||||||
| All others Ph-like |
REF 0.614 |
REF 0.193-1.952 |
REF .4087 |
REF 0.686 |
REF 0.208-2.267 |
REF .5366 |
REF 0.701 |
REF 0.255-1.924 |
REF .4903 |
REF 0.777 |
REF 0.274-2.203 |
REF .6351 |
| Hyperdiploid | ||||||||||||
| All others Hyperdiploid |
REF 0.451 |
REF 0.182-1.117 |
REF .0851 |
REF 0.445 |
REF 0.177-1.120 |
REF .0855 |
REF 0.577 |
REF 0.250-1.333 |
REF .1984 |
REF 0.572 |
REF 0.243-1.345 |
REF .2003 |
| ETV6/RUNX1 | ||||||||||||
| All others ETV6/RUNX1 |
REF 1.626 |
REF 0.780-3.388 |
REF .1946 |
REF 1.527 |
REF 0.709-3.290 |
REF .2797 |
REF 1.201 |
REF 0.483-2.984 |
REF .6936 |
REF 1.209 |
REF 0.475-3.077 |
REF .6903 |
Multivariate model adjusted for age, sex, blinatumomab exposure, and bone marrow disease at infusion.
*
Censored at 24 months because of small sample size beyond 24 months.